1. Transdermal drug TTTrrraaannnsssdddeeerrrmmmaaalll dddrrruuuggg ddddeeeelllliiiivvvveeeerrrryyyy ssssyyyysssstttteeeemmmm

2. Transdermal Therapeutic
Systems
vDiffusion of the medication (drug) through skin into
the systemic circulation for distribution and
therapeutic effect
2
vMost TDD systems use passive delivery

3. 13.1 Advantages of TTS’s
1. Eliminates oral absorption variables.
2. Eliminates first-pass metabolism
3. Provides controlled constant drug.
4. Can accommodate potent drugs
3
5. Permits self-administration
6. Non-invasive (no needles or injections)
7. Improves patient compliance
8. Easy treatment termination

4. Limitations of TDD Systems
• Poor diffusion of large molecules
• Skin irritation
4

5. TDD System Design Factors
• Therapeutic indication
• Desired drug delivery profile
- Dose level, duration, etc.
• Skin adhesion profile
• Application site
5
• Ease of application
• Patch size, shape, appearance, comfort
• Wear period
• Packaging
• Patch disposal
• Patch cost

6. 6
Process of transdermal permeation.

7. BASIC COMPONENTS OF TDDS
1.Polymer matrix
2.The drug
3.Permeation enhancers
4.Other excipients
1.Polymer matrix
Ideal polymer
٠MWT,and chemical functionality of the polymer should not affect the
diffusivity of drug and its release
7
٠stable
٠non reactive
٠easily manufactured
٠easily fabricated into desired product
٠inexpensive
٠degaradation product must be non toxic or non antagonistic to the host
٠ should retain its mechanical properties when the large amount of drug is
loaded in to it

8. Polymers used in TDDS
• Natural polymers
– Cellulose derivatives
– Zein
– Gelatin
– Shellac
– Waxes
– Proteins
– Gums
– Natural rubbers
– starch
8
• Synthetic elastomers
--polybutadiene
--hydrin rubber
--polysiloxone
--silicone rubber
--nitrile
--acrylonitrile
--butyl rubber
--styrene butadiene rubber
--neoprine etc.
• Synthetic polymers
PVA,PVC,PE,PP,Poly amide,Poly acrylate,Polyurea,PVP,PMMA,Epoxy etc.

9. 2. Suitable drug candidate
• Physico chemical properties of drug
– Should have MW less than 1000 daltons(500-1000)
– Should have affinity for both lipophilic and hydrophilic phases
– Should have low melting pont
• Biological properties of drug
– Should be potent(less than 20mg)
– Half life should be short
9
– Must not induce a cutaneous irritant or allergic response
– Drugs which degrade in the GI tract or inactivated by hepatic
first pass effect are suitable candidate
– Tolerance to the drug must not develop
– Drugs which has to be administered for a longer period of time
can be formulated
– Drugs which cause adverse effects to non target tissues can
also be formulated

10. 3.PERMEATION ENHANCERS
(to enhance stratum corneum permeability)
• Solvents
Increases penetration by swelling the polar pathway transport or fluidising lipids
Eg.water,ethanol,methanol,DMS,homologs of methyl sulphoxide,dimethyl
acetamide,and DMF,2-pyrrolidone,N-methyl,2-
pyrrolidone,laurocapram,PG,glycerol,silicone fluids,isopropyl palmitate.
• Surfactants
Enhances the polar pathway transport of hydrophilic drugs
• Anionic surfactants
Dioctyl sulpho succinate,SLS,deco decylmethyl sulphoxide etc.
10
• Non ionic surfactants
Pluronic F127,Pluronic F68,etc.
• Bile salts
Sodium taurocholate,sodium deoxy cholate,sodium tauroglycocholate.
• Binary systems
Propylene glucol-oleic acid and 1,4-butane diol-linoleic acid
• Miscellaneous
Urea-hydrating and keratolytic agent,N,N-dimethyl-m-toluamide,calcium
thioglycolate,anti cholinergic agents
• Potential permetion enhancers
Euclyptol,di-o-methyl-ß-cyclodextrin and soyabean casein

11. Permeability Coefficient Is the Critical
Predictor of Transdermal Delivery
Transport = Flux = (mg/cm2/sec) = P x A x (Cd – Cr)
Permeability Coefficient = P = D x K (cm/sec)
h
11
Where A = Surface area of patch
D = Diffusivity of drug in membrane (skin)
K = Partition coefficient (patch/skin)
C = Concentration in donor or receptor
(patch or skin)
h = Thickness of membrane (skin)

12. 4.OTHER EXCIPIENTS
• Adhesives
Ideal properties
• Should not irritate or sensitize the skin or affect normal functions of the skin
• Should adhere to the skin aggressively
• Should be easily removed
• Should not leave an un washable residue on the skin
• Should have an intimate contact with the skin
• Should be compatible with the drug,excipients and permeation enhancers
12
• Permeation of drug should not be affected
• Backing membrane
Ideal properties
• Flexible and provide good bond to the drug reservoir
• Prevent drug from leaving the dosage form
• Should be impermeable
• E.g.metallic plastic laminate,plastic backing with absorbent pad and
occlusive base plate,adhesive foam pad with occlusive base plate.

13. • Liner: Protects the drug during storage
and is removed prior to use
• Drug
• Adhesive: Serves to bind the components
of the patch to the skin
• Membrane: Controls the release of the
drug from the reservoir in certain types of
patches
• Backing: Protects the patch from the outer
environment.
13

14. Formulation of TDDS
1.Membrane-moderated or permeation controlled TDDS
• Drug reservoir(homogenous dispersion of drug with polymeric matrix or
suspension of drug in un leachable viscous liquid medium such as silicone
fluid) is encapsulated within drug impermeable metallic plastic laminate and
a rate controlling polymeric membrane(ethylene vinyl acetate co polymer)
• The cross sectional view of this system is shown in the following Fig.1
14

15. Reservoir Patches
• The reservoir system has a drug layer that
is separate from the adhesive.
15

16. Schematic Drawing of the Reservoir type of patch.
Film Backing
Drug Layer
Rate-controlling Membrane
16
Contact Adhesive
Protective Peel Strip (removed prior to use)
skin

17. Example of this system are
1.Nitro glycerin releasing TDDS (Transderm-
Nitro/ciba,USA)for once a day medication in angina
pectoris
2.Scopolamine releasing TDDS (Transderm-
Scop/ciba,USA)for 72 hrs.prophylaxis of motion sickness
3. Estradiol releasing TDDS (Estraderm/ciba)for treatment
17
of menopausal syndrome
4. Clonidine releasing TDDS (Catapres/Boehringer
Ingelheim)for 7 day therapy of hyper tension
5. Prostaglandin-derivatives TDDS

18. 2.Adhesive diffusion/dispersion-controlled
TDDS
Drug reservoir
• homogenous dispersion of drug with adhesive polymer(poly(isobutylene) or
poly acrylate)
• Then spreading of this medicated adhesive polymer on flat sheet of drug
impermeable metallic plastic backing to form thin drug reservoir layer
• On top of the drug reservoir layer,thin layers of rate controlling adhesive
polymer of specific permeability and constant thickness are applied to
produce an adhesive diffusion/dispersion-controlled TDDS
18
• The cross sectional view of this system is shown in the following Fig.2

19. Drug in Adhesive
Patches
• A system in which the drug is incorporated
directly into the adhesive, rather than into
a separate layer. Usually used for smaller
molecular weight compounds.
• These can be either a single layer or multi-layer.
19
• Sometimes referred to as the “matrix type
patch”

20. Schematic Drawing of the Matrix (Drug-in-Adhesive) type
of patch.
Film Backing
Drug/Adhesive Layer
20
Protective Liner (removed prior to use)
skin

21. Examples for this system
1.Iso sorbide dinitrate-releasing
TDDS
21
2.Verapamil releasing TDDS

22. • 3.Matrix diffusion-controlled TDDS
Drug reservoir
• homogenous dispersion of drug with hydrophilic or lipophilic polymer matrix by any
one of the following methods
• Homogenous dispersion of finely ground drug particles with liquid polymer or highly
viscous base polymer followed by cross linking of polymer chains
• Homogenous mixing of drug solid with rubbery polymer at an elevated temperature
• Dissolving the drug and polymer in a common solvent follwed by solvent evaporation
22
in a mould at an elevated temperature or under vaccum.
• Medicated polymer is moulded in to desired surface area and controlled thickness
• This medicated polymer disc is pasted on to an occlusive base plate with
impermeable plastic backing
• Then the adhesive polymer is spread along the circumference to form a strip of
adhesive rim around the medicated disc

23. Example of this system are
1.Nitro glycerin releasing TDDS (Nitro-Dur and Nitro-Dur II /Key pharmaceuticals,USA)
2. Estradiol di acetate releasing TDDS
3. Verapamil releasing TDDS
The cross sectional view of this system is shown in the following Fig.3
23

24. 4.Micro reservoir type/micro sealed dissolution-controlled
TDDS
Combination of the reservoir and matrix diffusion
Drug reservoir
•suspension of drug with aqueous solution of water soluble liquid polymer
•Homogenous dispersion of drug suspension in a lipophilic polymer(silicone elastomer)
•As a result discrete un leachable microscopic spheres of drug reservoir is formed which is stabilized by
cross linking
•Medicated polymer is moulded in to desired surface area and controlled thickness and it is coated with
24
a layer of bio compatible polymer to modify mechanism and rate of drug release
•This medicated polymer disc is pasted on to an occlusive base plate with impermeable plastic backing
•Then the adhesive polymer is spread along the circumference to form a strip of adhesive rim around
the medicated disc
Example of this system are
1.Nitro glycerin releasing TDDS (Nitrodisc /searle,USA)
The cross sectional view of this system is shown in the following Fig.4

25. 25

26. Products on the market, or in development include:
• Clonidine
• Works as an agonist of adrenaline at the
presynaptic α2 adrenergic
• Product name = Catapres-TTS®
• used to treat hypertension
26

27. • Ethinylestradiol (EO) and norelgestromin (N)
• Product name = Ortho-Evra®
• Used for Contraception
• Type of patch = Drug-in-Adhesive
• Frequency of application = weekly
27
OH
H
H H
HO
Ethinylestradiol (an estrogen)

28. • Fentanyl
• Product Name = Duragesic®
• Used for: Analgesia
• Type of Patch = Drug-in-Adhesive
• Frequency of Application = Weekly
28
O
N
N

29. • Lidocaine
• Product Name = Lidoderm®
• Used for: analgesia of postheretic neuralgia
(PHN), a painful condition caused by the
varicella zoster virus (herpes zoster = shingles)
• Type of Patch = Reservoir
• Frequency of Application = Daily
29

30. • Nicotine
• Product name = Habitrol®, Nicoderm –
CQ®, Nicotrol®, Prostep®
• Used for: Smoking cessation
• Frequency of administration = Daily
30

31. • Nitroglycerin
• Works by producing nitric oxide (NO), which then acts as
a vasodilator
• Product Names = Nitro-Dur®, Transderm-Nitro®
• Used for: Angina
• Type of Patch = Nitro-Dur is Drug-in-adhesive
Nitrodisc is reservoir
• Frequency of administration = Daily
31

32. • Estradiol
• Product Name = Alora®, Climara®, Esclim®,
Estraderm®, FemPatch®, Vivelle®, Vivelle-DOT®
• Used for: Hormone replacement
• Type of Patch: Drug-in-adhesive
• Frequency of application = weekly
32

33. • Estradiol + Norethindrone
• Product name = CombiPatch®
• Used for: Hormone Replacement
33
O
OH
H H
H H
Norethindrone

34. • Oxybutynin
• Works as competitive antagonist of the
muscarinic acetycholine receptor
• Product name = Oxytrol®
• Used for: Overactive bladder (antispasmodic)
• Type of Patch: Drug-in-adhesive
• Frequency of application = twice a week
34

35. • Scopolamine
• Works as competitive antagonist of acetylcholine
at the muscarinic receptor
• Product Name = Transderm Scop®
• Used for: Motion Sickness
35

36. • Testosterone
• Product Names = Androderm®, Testoderm
TTS®, Testoderm®
• Used for: Hypogonadism
36

37. • Lidocaine + Epinephrine
• Product name = Lidosite
• Used for: Dermal anesthesia
• Type of Patch = Reservoir,
iontophoretic.
Epinephrine acts as vasoconstrictor, thus prolonging the
duration of action of lidocaine (by delaying resorption) at the site
37

38. Manufacturer Trade name Drug Strength available
Ciba
Estraderm Estradiol 25 μg, 50 μg, 100 μg
Transderm-Scop Scopolamine 1.5 mg
Transderm-Nitro Nitroglycerin 0.1 mg, 0.2 mg
Janssen Duragesic Fentanyl 25 μg, 50 μg, 100 μg
38
Basel Habritol Nicotine 21 μg
Parke-Davis Nicotrol Nicotine 21 μg
Lederle Prostep Nicotine 21 μg

39. 39
TTS Available in market
Large scale mfg of TTS

40. Evaluation Parameters
üPhysical parameters
üEvaluation of adhesive
üIn-vitro testing
üIn-vivo assessment
üCutaneous metabolism
4400
üStability studies
üEvaluation of skin reactions.
7/19/2012 40

41. Thickness
4411
7/19/2012 41

42. Weight variation
4422
7/19/2012 42

43. Folding endurance
4433
7/19/2012 43

44. Moisture content
% Moisture content = Initial weight – Final weight X 100
4444
Final weight
7/19/2012 44

45. Moisture uptake
% moisture uptake = Final weight – Initial weight X 100
4455
Initial weight
7/19/2012 45

46. Flatness
% constriction = I1 – I2 X 100
I1
4466
I2 = Final length of each strip
I1 = Initial length of each strip
7/19/2012 46

47. Drug content
4477
7/19/2012 47

48. Water Vapor Transmission studies
4488
7/19/2012 48

49. Evaluation of adhesive
1} Peel adhesion properties
It is the force required to remove adhesive from test substrate.
4499
7/19/2012 49

50. 2} Tack properties
It is the ability of the polymer to adhere to substrate with little contact
pressure.
2.1} Thumb tack test
2.2} Rolling ball tack test
5500
7/19/2012 50

51. 2.3}Quick-stick (or peel-tack) test
5511
7/19/2012 51

52. 2.4} Probe tack test
5522
7/19/2012 52

53. 3} Shear strength properties
Shear strength is the measurement of the cohesive strength of adhesive polymer.
5533
7/19/2012 53

54. Tensile strength
Tensile strength= F/a.b (1+L/l)
F - the force required to break
a - width of film
5544
b - thickness of film
L - length of film
l - elongation of film at break point
7/19/2012 54

55. In-vitro testing
üThe Paddle over Disc
üThe Cylinder modified USP Basket
üThe reciprocating disc
üDiffusion Cells e.g. Franz Diffusion Cell and its modification Keshary-
5555
Chien Cell
7/19/2012 55

56. In-vitro testing
Importance
(1)Defining skin permeation kinetic studies using a
diffusion cell system and cadaver skin during the drug
5566
development process.
(2) in vitro drug release kinetics, to be used for batch-to-
batch release and as a compendial test.
7/19/2012 56

57. Preparation of skin ffoorr ppeerrmmeeaattiioonn ssttuuddiieess
l IInnttaacctt FFuullll tthhiicckknneessss sskkiinn
HHaaiirr rreemmoovvaall rreemmoovvaall ooff ssuubbccuuttaanneeoouuss
ttiissssuuee ddeerrmmiiss iiss cclleeaanneedd wwiitthh iissoopprrooppyyll
aallccoohhooll wwaasshheedd wwiitthh wwaatteerr
5577
ssttoorreedd aatt --2200°C
l SSeeppaarraattiioonn ooff eeppiiddeerrmmiiss ffrroomm ffuullll
tthhiicckknneessss sskkiinn:

58. 5588
K-C cell for permeation studies
7/19/2012 58

59. 5599

60. Effect of skin uuppttaakkee mmeettaabboolliissmm
6600

61. In-vivo assessment
1} Animal model
Mouse, hairless rat, hairless dog, hairless rhesus monkey,
6611
rabbit, guinea pig
7/19/2012 61

62. In-vivo assessment
2} Human model
Ø. Phase I clinical trials are conducted to determine mainly safety in
volunteers.
ØPhase II clinical trials determine short term safety and mainly effectiveness
6622
in patients.
Ø Phase III trials indicate the safety and effectiveness in large number of
patient population.
ØPhase IV trials at post marketing surveillance are done for marketed
patches to detect adverse drug reactions.
7/19/2012 62

63. Skin iirrrriittaattiioonn ssttuuddiieess
Contact dermatitis
l GGrroouupp II wwaass sseerrvveedd aass nnoorrmmaall,, wwiitthhoouutt
aannyy ttrreeaattmmeenntt..
l GGrroouupp IIII,, ccoonnttrrooll,, wwaass aapppplliieedd wwiitthh
6633
mmaarrkkeetteedd aaddhheessiivvee ttaappee..
l GGrroouupp IIIIII TTrraannssddeerrmmaall ssyysstteemmss ((bbllaannkk))
l GGrroouupp IIVV TTrraannssddeerrmmaall ssyysstteemmss ((ddrruugg
llooaaddeedd))
l GGrroouupp VV ssttaannddaarrdd iirrrriittaanntt ..

64. Evaluation of skin reactions.
6644
7/19/2012 64

65. Stability studies
6655
7/19/2012 65

66. Study Storage conditions Time period
Temperature Relative
humidity
Long Term 25°C± 2°C
60%± 5%
12 months
6666
OR
30°C± 2°C
OR
65%± 5%
Intermediate 30°C± 2°C 65%± 5% 6 months
Accelerated 40°C± 2°C 75%± 5% 6 months

67. APPLICATIONS
6677
7/19/2012 67

68. The Past
• 3000 BC--Pharmaceuticals and plasters first
recorded in Babylonia.
• 1500 BC--Plasters recorded in the Ebers
Papyrus (Egypt).
6688
• Plasters made by physicians or pharmacists at
the time of dispensing
7/19/2012 68

69. The Past
Plasters, Poultices aanndd CCeerraatteess
• Used for topical and deep tissues
• Counterirritants, protective dressings, belladonna,
salicylic acid, flaxseed, mustard,
6699
• Adhered to skin with stiff ointments, waxes,
melted waxes and rubber resins, kaolin
• Applied hot, could absorb water
• Backings made of cloth or animal skin
7/19/2012 69

70. The Past: Adhesives
Example of plaster formula (1909)
Rubber 20 grams
Petrolatum 20 grams
Lead Plaster 960 grams
7700
To make, 1000 grams
Add any one of the following Belladonna Leaves,
Oleoresin of Capsicum, Mercury, Opium, Soap
7/19/2012 70

71. The Past
The last 150 years:
• Electrically assisted applications first occurred
in late 1800s and in early 1900s.
• Rubber became available in the 1800s
7711
• Nitroglycerin was applied topically as an
ointment for delivery to the bloodstream in
the 1950 to present.
• Belladonna, capsicum, mustard and salicylic
acid plasters
7/19/2012 71

72. The Present Day
• 1970-- Alza Research (US) began first
development of the modern transdermal
• 1980-- Scopolamine first transdermal reached
US
7722
• 2002– Many Rx and non-RX products in US
market.
• Transdermals deliver drugs from a few hours
up to 7 days.
7/19/2012 72